版本:
中国

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

June 15 TG Therapeutics Inc

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

* Announces follow-up data from triple combination of tg-1101, tgr-1202, and bendamustine in patients with dlbcl and fl

* 100% orr, including 50% cr rate in patients with relapsed diffuse large b-cell lymphoma (dlbcl) Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐